SAN DIEGO, Aug. 24, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, promoted Sheela Mohan-Peterson, JD, MS, to Chief Legal and Compliance Officer, effective August 24, 2015. In this role, Ms. Mohan-Peterson will advise the Company's officers and Board of Directors on all major legal matters and continue to lead the Company's intellectual property portfolio and global legal strategy.
"Sheela has provided valuable leadership and counsel, which has contributed to the growth and success of OncoSec over the past year," said Punit Dhillon, President and CEO of OncoSec. "Her extensive legal expertise has allowed us to expand our intellectual property portfolio by leveraging our R&D and preclinical activities. I expect Sheela will continue to balance risks and opportunities as we navigate new business growth opportunities in this expanded role."
Ms. Mohan-Peterson has spent 29 years working in the pharmaceutical and biotech industries and joined OncoSec in September 2014, serving as General Counsel and Corporate Secretary. She was most recently a Senior Patent Counsel at Merck & Co., Inc. Ms. Mohan-Peterson also held patent counsel positions at several companies including: Schering-Plough Biopharma, DNAX Research Institute, Incyte Genomics, and Roche Bioscience. She received her bachelor's degree in Biology from Washington University in St. Louis, her master's degree in Biology from Rutgers University, and her law degree from Peninsula (now Lincoln) University (CA).
About OncoSec Medical Incorporated OncoSec is a biopharmaceutical company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck (HNSCC), and triple-negative breast cancer (TNBC). In addition to ImmunoPulse™ IL-12, the company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
CONTACT: Investor Relations: Jordyn Kopin OncoSec Medical Incorporated 855-662-6732 firstname.lastname@example.org
Media Relations: Mary Marolla OncoSec Medical Incorporated 855-662-6732 email@example.com
SOURCE OncoSec Medical Incorporated